{
  "items": "9",
  "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish",
  "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.",
  "feed": [
    {
      "title": "Zura Bio (NASDAQ: ZURA) discloses resignation of director Arnout Ploos",
      "url": "https://www.stocktitan.net/sec-filings/ZURA/8-k-zura-bio-ltd-reports-material-event-6692f99df211.html",
      "time_published": "20251219T010946",
      "authors": [
        "NULL"
      ],
      "summary": "Zura Bio Limited reported that Arnout Ploos van Amstel resigned from its Board of Directors and the Nominating and Governance Committee, effective December 11, 2025. The company stated that his resignation was not due to any disagreement with its operations, policies, or practices. This disclosure is a standard governance change for the emerging growth company, whose Class A ordinary shares trade on Nasdaq under the symbol ZURA.",
      "banner_image": "NULL",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.813872"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.734875"
        }
      ],
      "overall_sentiment_score": 0.04032,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ZURA",
          "relevance_score": "0.311589",
          "ticker_sentiment_score": "0.018727",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Zura Bio Reports Third Quarter 2025 Financial Results and Recent Corporate Updates",
      "url": "https://www.businesswire.com/news/home/20251113296574/en/Zura-Bio-Reports-Third-Quarter-2025-Financial-Results-and-Recent-Corporate-Updates",
      "time_published": "20251117T035132",
      "authors": [],
      "summary": "Zura Bio Limited announced its third-quarter 2025 financial results, highlighting the progression of two Phase 2 clinical trials for tibulizumab in hidradenitis suppurativa and systemic sclerosis, with topline data expected in mid-to-late 2026. The company reported $139.0 million in cash and cash equivalents, projected to fund operations through 2027. Research and development expenses increased due to trial advancement, while general and administrative expenses decreased year-over-year.",
      "banner_image": "https://mms.businesswire.com/media/20251113296574/en/1763843/4/Zura_Bio_Logo.jpg",
      "source": "Business Wire",
      "category_within_source": "General",
      "source_domain": "Business Wire",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.942716"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.824181"
        }
      ],
      "overall_sentiment_score": 0.148334,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ZURA",
          "relevance_score": "0.961735",
          "ticker_sentiment_score": "0.256149",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MRNA",
          "relevance_score": "0.555614",
          "ticker_sentiment_score": "0.078320",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.553819",
          "ticker_sentiment_score": "0.064169",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.535327",
          "ticker_sentiment_score": "0.075730",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "ZURA BIO Earnings Preview: Recent $ZURA Insider Trading, Hedge Fund Activity, and More",
      "url": "https://www.quiverquant.com/news/ZURA+BIO+Earnings+Preview%3A+Recent+%24ZURA+Insider+Trading%2C+Hedge+Fund+Activity%2C+and+More",
      "time_published": "20251114T210600",
      "authors": [
        "Quiver EarningsTracker"
      ],
      "summary": "ZURA BIO ($ZURA) is scheduled to release its quarterly earnings data on November 17th, with analysts expecting $0 revenue and -$0.19 EPS. The article details recent hedge fund activity, showing significant share additions and removals by institutional investors in Q2 and Q3 2025. It also highlights recent analyst ratings, with 3 firms issuing \"Buy\" ratings and a median price target of $13.0 among the 4 analysts.",
      "banner_image": "NULL",
      "source": "Quiver Quantitative",
      "category_within_source": "General",
      "source_domain": "Quiver Quantitative",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.909240"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.700998"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.615941"
        }
      ],
      "overall_sentiment_score": 0.024539,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ZURA",
          "relevance_score": "0.349213",
          "ticker_sentiment_score": "0.035126",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Zura Bio Announces Chief Financial Officer Transition",
      "url": "https://www.quantisnow.com/insight/zura-bio-announces-chief-financial-officer-transition-6104676",
      "time_published": "20250701T063000",
      "authors": [],
      "summary": "Zura Bio has announced Eric Hyllengren will become its new Chief Financial Officer, effective July 7, 2025. He succeeds Verender Badial, who will facilitate a smooth transition through July 31, 2025. Mr. Hyllengren brings over 20 years of financial leadership experience in the life sciences and biotechnology sectors, most recently serving as COO and CFO at Atara Biotherapeutics.",
      "banner_image": "https://mms.businesswire.com/media/20250701021645/en/2511994/4/E_Hyllegren.jpg",
      "source": "Quantisnow",
      "category_within_source": "General",
      "source_domain": "Quantisnow",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.910644"
        },
        {
          "topic": "finance",
          "relevance_score": "0.739837"
        }
      ],
      "overall_sentiment_score": 0.274191,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ZURA",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.348168",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.603668",
          "ticker_sentiment_score": "0.213841",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "After losing 43% in the past year, Zura Bio Limited (NASDAQ:ZURA) institutional owners must be relieved by the recent gain",
      "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zura/zura-bio/news/after-losing-43-in-the-past-year-zura-bio-limited-nasdaqzura",
      "time_published": "20250203T021019",
      "authors": [
        "Simply Wall St"
      ],
      "summary": "Institutional investors, holding 44% of Zura Bio Limited (NASDAQ:ZURA), are likely relieved by a recent US$14m market cap gain, especially after experiencing 43% losses over the past year. The top 10 shareholders collectively own over half the company's shares. Alongside institutional and private equity ownership, insiders hold a US$6.8m stake, and the general public owns 18% of the company.",
      "banner_image": "https://images.simplywall.st/asset/chart/1783060399-ownership-breakdown-1-dark/1738580067497",
      "source": "Simply Wall Street",
      "category_within_source": "General",
      "source_domain": "Simply Wall Street",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.939401"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.823161"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.747265"
        },
        {
          "topic": "finance",
          "relevance_score": "0.636398"
        }
      ],
      "overall_sentiment_score": 0.144749,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ZURA",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.143830",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Zura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis",
      "url": "https://www.businesswire.com/news/home/20241223167603/en/Zura-Bio-Launches-Global-Phase-2-TibuSURE-Study-to-Evaluate-Tibulizumab-in-Adults-With-Systemic-Sclerosis",
      "time_published": "20241231T235959",
      "authors": [],
      "summary": "Zura Bio (Nasdaq: ZURA) has initiated TibuSURE, a global Phase 2 study to evaluate tibulizumab for treating systemic sclerosis (SSc) in adults. Tibulizumab is a novel dual-pathway antibody targeting both IL-17A and BAFF, aiming for deeper efficacy in this life-threatening autoimmune disease. The study, involving approximately 80 participants, will assess safety, tolerability, and efficacy over a 24-week period, with key endpoints including skin score, lung function, and physical function.",
      "banner_image": null,
      "source": "Business Wire",
      "category_within_source": "General",
      "source_domain": "Business Wire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.919974"
        }
      ],
      "overall_sentiment_score": 0.408834,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ZURA",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.435428",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Zura Bio Ltd re-elects board, ratifies auditor at AGM By Investing.com",
      "url": "https://in.investing.com/news/company-news/zura-bio-ltd-reelects-board-ratifies-auditor-at-agm-93CH-4495913",
      "time_published": "20241030T035132",
      "authors": [],
      "summary": "Zura Bio Ltd. announced that shareholders re-elected all nine director nominees to the company's Board of Directors and ratified the re-appointment of WithumSmith+Brown, PC as the independent registered public accounting firm during its Annual General Meeting on October 23, 2024. Despite not being profitable currently, with a negative operating income of $41.15 million, the company holds more cash than debt and its liquid assets exceed short-term obligations. Piper Sandler has maintained an Overweight rating on Zura Bio, anticipating significant milestones with upcoming Phase 2 initiations.",
      "banner_image": "https://i-invdn-com.investing.com/news/news_pile_69x52._800x533_L_1419494209.jpg",
      "source": "Investing.com India",
      "category_within_source": "General",
      "source_domain": "Investing.com India",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.923552"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.835943"
        },
        {
          "topic": "finance",
          "relevance_score": "0.746594"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.631875"
        }
      ],
      "overall_sentiment_score": 0.188102,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ZURA",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.228186",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Zura Bio Names Robert Lisicki as CEO & Director of the Board",
      "url": "https://www.contractpharma.com/breaking-news/zura-bio-names-robert-lisicki-as-ceo-director-of-the-board/",
      "time_published": "20240408T000000",
      "authors": [
        "Charlie Sternberg"
      ],
      "summary": "Zura Bio Limited has appointed Robert Lisicki as Chief Executive Officer and Director of the Board, succeeding founding CEO Dr. Someit Sidhu. Lisicki brings extensive experience from leadership roles at Arena Pharmaceuticals, Regeneron, InCarda Therapeutics, Daiichi Sankyo, and Amgen, and is expected to drive Zura Bio's growth as a leading immunology company.",
      "banner_image": null,
      "source": "Contract Pharma",
      "category_within_source": "General",
      "source_domain": "Contract Pharma",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.912498"
        },
        {
          "topic": "finance",
          "relevance_score": "0.713718"
        }
      ],
      "overall_sentiment_score": 0.323986,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ZURA",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.482046",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "REGN",
          "relevance_score": "0.627528",
          "ticker_sentiment_score": "0.132963",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Zura Bio Limited Announces Share Redemptions and Lock-up Agreement",
      "url": "https://www.businesswire.com/news/home/20230327005458/en/Zura-Bio-Limited-Announces-Share-Redemptions-and-Lock-up-Agreement",
      "time_published": "20230327T021259",
      "authors": [
        "NULL"
      ],
      "summary": "Zura Bio Limited announced that 13,617,502 Class A ordinary shares, or 98.7% of all issued and outstanding Class A ordinary shares, were validly redeemed by JATT's public shareholders in connection with their business combination. Additionally, Zura entered into a lock-up agreement with Athanor Master Fund, LP and Athanor International Master Fund, LP, restricting transfer of 2,500,000 shares until March 20, 2024. This follows their previously announced business combination closing with JATT Acquisition Corp.",
      "banner_image": "https://mms.businesswire.com/media/20230327005458/en/1747863/4/Zurabio_logo_colour.jpg",
      "source": "Business Wire",
      "category_within_source": "General",
      "source_domain": "Business Wire",
      "topics": [
        {
          "topic": "mergers_and_acquisitions",
          "relevance_score": "0.908852"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.840539"
        },
        {
          "topic": "finance",
          "relevance_score": "0.715644"
        }
      ],
      "overall_sentiment_score": 0.101885,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ZURA",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.105600",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    }
  ]
}